Guide to Cell Therapy GxP: Quality Standards in the Development of Cell-Based Medicines in Non-Pharmaceutical Environments provides a practical guide to the implementation of quality assurance systems for successful performance of all cell-based clinical trials.
The book includes all information that should be used in investigational medicinal product dossier (IMPD), the launching point for any clinical investigation, and beyond, bridging the gap in knowledge with the inclusion of examples of design of GLP-compliant preclinical studies, design of bioprocesses for autologous/allogeneic therapies, risk-based assessment of GMP-compliant processes for the production of cell-based therapies, and instructions on how to implement GLP/GMP standards in centers accredited with other quality assurance standards (JACIE; FACT/NETCORD, ISO9001, and others).
- Provides easy access to important information on current regulations, state-of-the-art techniques, and recent advances otherwise scattered on various funding websites, within conference proceedings, or maintained in local knowledge
- Features protocols, techniques for trouble-shooting common problems, and an explanation of the advantages and limitations of a technique in generating conclusive data
- Includes practical examples of successful implementation of quality standards
Muu info
This book provides the quality standards used in the development of stem cell-based medicines in non-pharmaceutical environments, and includes all information that should be used in investigational medicinal product dossier (IMPD), the launching point for any clinical investigation.
|
|
ix | |
Foreword |
|
xi | |
Preface |
|
xiii | |
|
1 Overview of the Development Program of a Cell-Based Medicine |
|
|
1 | (14) |
|
|
|
1 | (3) |
|
2 Key Pharmaceutical Factors to Consider in Early Development Stages |
|
|
4 | (1) |
|
3 TPP: Beginning with the End in Mind |
|
|
5 | (1) |
|
4 Stages of Drug Development |
|
|
6 | (2) |
|
5 Considering Stakeholders |
|
|
8 | (1) |
|
6 Product Lifecycle and Portfolio Management |
|
|
9 | (1) |
|
7 Performance Management and the Check Point Value |
|
|
10 | (1) |
|
|
11 | (4) |
|
|
12 | (1) |
|
|
13 | (1) |
|
List of Acronyms and Abbreviations |
|
|
13 | (2) |
|
2 European Regulatory Framework for the Development of Cell-Based Medicines |
|
|
15 | (34) |
|
|
|
|
16 | (1) |
|
2 What Cell-Based Products are Considered as Medicinal Products? The Legal Definitions and Main Regulations Applying to Cell-Based Products |
|
|
16 | (7) |
|
3 An Introduction to Cell-Based Medicine Development: Roadmap |
|
|
23 | (9) |
|
4 Regional and National Institutions Supporting Cell Therapy Translational Research |
|
|
32 | (1) |
|
5 European Regulation for Advanced Therapy Medicinal Products Not Intended to be Placed on the Market: Hospital Exemption and Its National Interpretation |
|
|
33 | (8) |
|
|
41 | (8) |
|
|
41 | (8) |
|
3 Nonclinical Studies for Cell-Based Medicines |
|
|
49 | (58) |
|
|
|
|
|
|
|
49 | (3) |
|
2 Types of Cell-Based Advanced Therapy Medicinal Products and their Safety Considerations |
|
|
52 | (5) |
|
3 Regulations and Nonclinical Studies |
|
|
57 | (3) |
|
4 Nonclinical Assessment---The Risk-Based Approach |
|
|
60 | (5) |
|
5 The Requirement for Good Laboratory Practice |
|
|
65 | (3) |
|
6 General Study Design Considerations |
|
|
68 | (11) |
|
7 Specific Nonclinical Safety Considerations |
|
|
79 | (19) |
|
|
98 | (9) |
|
|
99 | (5) |
|
|
104 | (1) |
|
List of Acronyms and Abbreviations |
|
|
105 | (2) |
|
4 Good Manufacturing Practice Compliance in the Manufacture of Cell-Based Medicines |
|
|
107 | (70) |
|
|
|
108 | (1) |
|
|
109 | (4) |
|
|
113 | (7) |
|
4 Qualification and Validation |
|
|
120 | (9) |
|
|
129 | (8) |
|
|
137 | (10) |
|
|
147 | (10) |
|
|
157 | (10) |
|
9 Inspections, Audits, Complaints, Recalls, and Returns |
|
|
167 | (4) |
|
|
171 | (6) |
|
|
171 | (1) |
|
|
172 | (2) |
|
|
174 | (3) |
|
5 Good Clinical Practice in Nonprofit Institutions |
|
|
177 | (54) |
|
|
|
|
|
178 | (7) |
|
2 The Elements of GCP Compliance |
|
|
185 | (8) |
|
3 The Clinical Trial Protocol |
|
|
193 | (3) |
|
4 The Investigator's Brochure |
|
|
196 | (6) |
|
|
202 | (2) |
|
6 Essential Documents for Clinical Trial |
|
|
204 | (8) |
|
|
212 | (7) |
|
8 Sponsor' Study Audit and Inspections |
|
|
219 | (6) |
|
|
225 | (6) |
|
|
225 | (2) |
|
|
227 | (2) |
|
List of Acronyms and Abbreviations |
|
|
229 | (2) |
|
6 Compatibility of GxP with Existing Cell Therapy Quality Standards |
|
|
231 | |
|
|
|
1 Quality Standards in Cell Therapy |
|
|
232 | (2) |
|
2 Adaptation of Existing Standards to GxP |
|
|
234 | (8) |
|
3 Impact of GxP Implementation |
|
|
242 | (1) |
|
|
243 | (1) |
|
5 Recommendations for Optimizing Integration of QA Systems |
|
|
244 | (1) |
|
|
245 | |
|
|
246 | (3) |
|
|
249 | (2) |
|
|
251 | (2) |
|
|
253 | |
Dr. Vives has specialties in GLP/GMP implementation, the development of (stem) cell-based products for regenerative medicine, and design, execution and analysis of non-clinical studies. He was a post-doctoral Fellow at University of Edinburgh and moved to Stem Cell Sciences Ltd in the UK where he became Head of Research. Six years ago, he became Head of Preclinical Studies at XCELIA, a biopharmaceutical company formed from The Catalan Blood and Tissue Service (Banc de Sang i Teixits) devoted to the development of advanced therapy medicine. As the Quality manager at XCelia, Dr. Vives secured the facility as the first GLP-compliant laboratory in Spain dedicated to the development of advanced cell therapies. He is now Director of R&D, responsible for technology transfer of innovative experimental bioprocesses into GMP-compliant production environments. He also manages GLP test facilities and relationships with Health Regulatory Agencies among other compliance responsibilities. Dr. Carmona is a Pharmacist with experience in management and training. She also holds a Masters Degree in Manufacturing of Advanced Therapy Medicinal Products and has worked across Europe in the biotechnology sector training on quality systems and good manufacturing practices in advanced therapies medicinal products. She has been a Quality Assessment Manager and GMP facilities Manager from the inception of the Andalusian Initiative for Advanced Therapies in October 2008. Previously, she worked worked as Quality Assessment and Accreditation Manager in the Andalusian Program for Cell Therapy and Regenerative Medicine. She has also worked as a Quality Assurance Technician at Cellerix an international biotech headquartered in Belgium, Cambridge, and Madrid and Clinical Documentation Technician in Pfizer.